These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24989307)

  • 21. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal/Measurable Residual Disease Detection in Acute Leukemias by Multiparameter Flow Cytometry.
    Fuda F; Chen W
    Curr Hematol Malig Rep; 2018 Dec; 13(6):455-466. PubMed ID: 30446941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry.
    Rihova L; Vsianska P; Bezdekova R; Kralova R; Penka M; Krejci M; Pour L; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):21-28. PubMed ID: 28903567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection of minimal residual disease in children leukemia patients by using PCR - review].
    He YY; Ye TZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun; 15(3):652-6. PubMed ID: 17605887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
    Luria D; Rosenthal E; Steinberg D; Kodman Y; Safanaiev M; Amariglio N; Avigad S; Stark B; Izraeli S;
    Cytometry B Clin Cytom; 2010 Nov; 78(6):365-71. PubMed ID: 20632326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Flow cytometric monitoring of minimal residual diseases in patients with acute leukemia after allogeneic hemapoietic stem cell transplantation].
    Gao YQ; Wu T; Wang H; Tong CR; Zhang WJ; Wang JB; Lu Y; Zhao YL; Zhou JR; Sun Y; Zhang YC; Ji SQ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):84-7. PubMed ID: 22730653
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of minimal residual disease in acute leukemia patients.
    van Dongen JJ; Szczepański T; de Bruijn MA; van den Beemd MW; de Bruin-Versteeg S; Wijkhuijs JM; Tibbe GJ; van Gastel-Mol EJ; Groeneveld K; Hooijkaas H
    Cytokines Mol Ther; 1996 Jun; 2(2):121-33. PubMed ID: 9384697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.
    Al-Mawali A; Gillis D; Lewis I
    Am J Clin Pathol; 2009 Jan; 131(1):16-26. PubMed ID: 19095561
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
    Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
    Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Minimal residual disease detection in acute leukemia patients by flow cytometric assay of cross-lineage antigen expression].
    Cho YU; Park CJ; Cha CH; Chi HS; Jang S; Kim MJ; Lee KH; Lee JH; Lee JH; Seo JJ; Im HJ
    Korean J Lab Med; 2010 Dec; 30(6):533-9. PubMed ID: 21157135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of minimal residual disease in acute myeloid leukemia.
    Buccisano F; Maurillo L; Spagnoli A; Del Principe MI; Ceresoli E; Lo Coco F; Arcese W; Amadori S; Venditti A
    Curr Opin Oncol; 2009 Nov; 21(6):582-8. PubMed ID: 19667983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges.
    Gaipa G; Buracchi C; Biondi A
    Expert Rev Mol Diagn; 2018 Sep; 18(9):775-787. PubMed ID: 30047795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical significance of sequential monitoring minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
    Wang L; Jiang H; Li H; Shao JB; Lu ZH; Yang JW; Yang WQ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):400-3. PubMed ID: 21781499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
    Soh KT; Tario JD; Wallace PK
    Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group.
    Borowitz MJ; Pullen DJ; Winick N; Martin PL; Bowman WP; Camitta B
    Cytometry B Clin Cytom; 2005 Nov; 68(1):18-24. PubMed ID: 16184615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Neale GA; Coustan-Smith E; Stow P; Pan Q; Chen X; Pui CH; Campana D
    Leukemia; 2004 May; 18(5):934-8. PubMed ID: 15029212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.